Kratom Syrup Reduces Colitis Severity and Strengthens Gut Barrier in Mouse Study, Supporting Traditional Anti-Diarrheal Use

Why it matters

Kratom has been used in traditional Thai medicine for gastrointestinal conditions for centuries, but scientific evidence has been scarce. This mouse study provides the first controlled data showing kratom syrup can reduce colitis severity and repair the gut barrier — findings relevant for both IBD research and kratom's long-term therapeutic development.

The big picture

As kratom faces intensifying regulatory scrutiny focused almost entirely on its opioid properties, this study highlights an underexplored dimension: its traditional role as a gut medicine may have real pharmacological basis. IBD affects millions globally, and existing treatments often fail — making kratom's mechanisms worth further study.

Key findings

• • Kratom syrup (KS) significantly reduced disease activity index (DAI) scores in acetic acid-induced colitis mice at 5 and 10 mg/kg mitragynine-equivalent doses
• • The 10 mg/kg dose delayed upper intestinal transit and improved total gut transit time comparably to loperamide (a standard anti-diarrheal)
• • Both KS5 and KS10 restored colon length to near-normal, while loperamide and the highest dose (KS20) did not
• • Kratom treatment enhanced distal colon barrier function: increased transepithelial electrical resistance (TEER) and reduced permeability
• • Normalized expression of claudin-2 and occludin — two proteins critical to tight-junction integrity — suggesting a mechanism beyond opioid receptor modulation

What they say

Animal study using acetic acid-induced colitis in ICR mice; 5 treatment groups including mitragynine doses of 5, 10, and 20 mg/kg; Prince of Songkla University, Thailand; Phytomedicine Plus, 2026.

Bottom line

Kratom's traditional anti-diarrheal properties appear to involve real intestinal barrier mechanisms, not just motility suppression — a finding that could open a new lane of kratom research well outside the opioid framework.